Physician
Aurora Health Care North, INC.
Aurora Health Care North, INC. was paid $6.80M by Medicaid between Jan 2018 and Dec 2024, across 158 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.
33Billing provider infoAURORA HEALTH CARE NORTH, INC.
TWO RIVERS, WI 54241
TWO RIVERS, WI 54241
33aNPI1477508687assigned 05/24/2006
33bProvider typeSurgery Physician
28Total paid$6.80M
24GClaims298,178
24DCodes billed158
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Surgery Physician providers in Wisconsin
Rank by total paid#3 of 22
Median peer was paid$15K
This provider vs. median444×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RICHARDSON, KARA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 35,076 | $811K | |
| 2019 | 37,710 | $876K | |
| 2020 | 35,627 | $821K | |
| 2021 | 48,580 | $1.01M | |
| 2022 | 49,859 | $1.10M | |
| 2023 | 52,655 | $1.19M | |
| 2024incomplete | 38,671 | $996K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 18,030 | 15,834 | $1.04M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 17,420 | 15,596 | $811K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 12% | 23,512 | 8,599 | $786K |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.6% | 4,368 | 3,613 | $583K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.4% | 8,876 | 7,900 | $439K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.5% | 4,436 | 3,980 | $309K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 3.5% | 12,059 | 4,835 | $238K |
| 80053 | Comprehensive metabolic panel | 3.4% | 12,416 | 9,929 | $233K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.5% | 2,254 | 2,039 | $167K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.1% | 2,942 | 2,652 | $141K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 1,979 | 1,778 | $139K |
| 97161 | 1.7% | 2,842 | 2,632 | $116K |
146 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 2,049 | $116K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.5% | 1,032 | $104K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 14,784 | $94K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.4% | 1,001 | $93K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 1,114 | $80K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 1,615 | $74K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.1% | 3,067 | $74K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 734 | $59K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,798 | $58K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,451 | $56K |
| G0378 | Hospital observation service, per hour | <1% | 1,675 | $52K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,767 | $51K |
| 83880 | <1% | 1,646 | $51K | |
| 84484 | <1% | 4,868 | $50K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,168 | $44K |
| 97162 | <1% | 1,176 | $42K | |
| 81025 | <1% | 3,770 | $40K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,568 | $35K |
| 82077 | <1% | 1,211 | $35K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 406 | $32K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 354 | $31K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 538 | $31K |
| 82962 | <1% | 3,380 | $30K | |
| 83735 | <1% | 5,617 | $28K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 544 | $27K |
| 83690 | <1% | 4,472 | $25K | |
| 83605 | <1% | 2,730 | $25K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,764 | $24K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 195 | $24K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 416 | $22K |
| 81001 | <1% | 4,467 | $22K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 288 | $21K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 281 | $17K |
| 84145 | <1% | 891 | $17K | |
| 81003 | <1% | 2,388 | $15K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 2,478 | $15K |
| 85379 | <1% | 1,808 | $14K | |
| 87081 | <1% | 216 | $13K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 42 | $11K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 52 | $10K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 416 | $9K |
| 87040 | <1% | 747 | $9K | |
| 80143 | <1% | 745 | $9K | |
| 86140 | <1% | 1,645 | $9K | |
| 80179 | <1% | 706 | $9K | |
| 97035 | <1% | 714 | $7K | |
| 85610 | <1% | 2,151 | $7K | |
| 97165 | <1% | 193 | $6K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 16 | $6K |
| 85730 | <1% | 1,304 | $6K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 12 | $5K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,860 | $5K |
| 87077 | <1% | 209 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 239 | $4K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 41 | $4K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 74 | $3K |
| 71250 | <1% | 88 | $3K | |
| 87186 | <1% | 313 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,739 | $2K |
| 97597 | <1% | 67 | $2K | |
| 93017 | <1% | 41 | $2K | |
| 82805 | <1% | 53 | $2K | |
| 0240U | <1% | 54 | $2K | |
| 97116 | <1% | 115 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,652 | $1K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,968 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,651 | $1K |
| 93975 | <1% | 27 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 26 | $1K |
| 82550 | <1% | 203 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 27 | $983.36 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 25 | $975.59 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 22 | $909.23 |
| 97166 | <1% | 28 | $887.26 | |
| 76536 | <1% | 26 | $870.86 | |
| 93971 | <1% | 56 | $776.12 | |
| 76830 | Ultrasound, transvaginal | <1% | 27 | $517.76 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,078 | $474.52 |
| A6223 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 23 | $474.21 |
| 86850 | <1% | 43 | $428.94 | |
| 94729 | <1% | 13 | $404.66 | |
| 85652 | <1% | 197 | $397.77 | |
| 71271 | <1% | 14 | $389.39 | |
| 87070 | <1% | 15 | $385.63 | |
| 82565 | <1% | 13 | $380.82 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 100 | $365.91 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 14 | $315.41 |
| 84702 | <1% | 19 | $226.43 | |
| 94726 | <1% | 13 | $187.04 | |
| 97032 | <1% | 14 | $174.60 | |
| 82150 | <1% | 30 | $162.01 | |
| 96376 | <1% | 1,135 | $161.02 | |
| 86901 | <1% | 60 | $144.21 | |
| 86900 | <1% | 60 | $144.21 | |
| 82728 | <1% | 13 | $143.34 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,552 | $115.78 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 128 | $86.23 |
| 84703 | <1% | 12 | $86.09 | |
| 74018 | <1% | 30 | $83.97 | |
| 94060 | <1% | 15 | $81.22 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,303 | $67.90 |
| 87205 | <1% | 15 | $62.18 | |
| 85027 | <1% | 18 | $54.73 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,872 | $18.48 |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | <1% | 53 | $15.86 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,804 | $10.72 |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,411 | $5.73 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,787 | $5.41 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,692 | $3.44 |
| J2704 | Injection, propofol, 10 mg | <1% | 6,296 | $0.93 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 863 | $0.38 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,060 | $0.29 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 62 | $0.10 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 2,317 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 244 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 2,694 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 4,167 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 5,697 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 3,042 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 676 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 715 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 232 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 127 | $0.00 |
| 76801 | 0% | 12 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 90 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 13 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 22 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 34 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 45 | $0.00 |
| 88300 | 0% | 17 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 243 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 885 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 430 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 907 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 250 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 162 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 982 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 378 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 84 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 247 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 162 | $0.00 |
| 73630 | 0% | 28 | $0.00 | |
| 73610 | 0% | 31 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 81 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 21 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 81 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRICHARDSON, KARA (VP MANAGED HEALTH)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.